{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:56:52Z","timestamp":1781873812270,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08343-3","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:13:33Z","timestamp":1781187213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TRPML1 agonists synergize with enzyme replacement therapy in fibroblasts from Pompe disease patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Carla","family":"Damiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Tarallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Strollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Minopoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Valanzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Assunto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Tuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Brunetti-Pierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ballabio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolina Cristina","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-5748","authenticated-orcid":false,"given":"Giancarlo","family":"Parenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"8343_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajmg.c.31318","volume":"160C","author":"M Kroos","year":"2012","unstructured":"Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160C:59\u201368. https:\/\/doi.org\/10.1002\/ajmg.c.31318.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"8343_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"van der Ploeg At","year":"2008","unstructured":"van der Ploeg At, Reuser AJ, van der Ploeg AT. Pompe\u2019s disease. Lancet. 2008;372:1342\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(08)61555-X.","journal-title":"Lancet"},{"issue":"1","key":"8343_CR3","first-page":"45","volume":"26","author":"N Raben","year":"2007","unstructured":"Raben N, Roberts A, Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 2007;26(1):45\u201348.","journal-title":"Acta Myol"},{"issue":"1","key":"8343_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ajmg.c.31317","volume":"160C","author":"N Raben","year":"2012","unstructured":"Raben N, Wong A, Ralston E, et al. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet Pt C. 2012;160C(1):13\u201321. https:\/\/doi.org\/10.1002\/ajmg.c.31317.","journal-title":"Am J Med Genet Pt C"},{"key":"8343_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","volume":"6","author":"J-A Lim","year":"2014","unstructured":"Lim J-A, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177. https:\/\/doi.org\/10.3389\/fnagi.2014.00177.","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"8343_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","volume":"11","author":"J-A Lim","year":"2015","unstructured":"Lim J-A, Li L, Kakhlon O, et al. Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy. 2015;11(2):385\u2013402. https:\/\/doi.org\/10.1080\/15548627.2015.1009779.","journal-title":"Autophagy"},{"key":"8343_CR7","doi-asserted-by":"publisher","unstructured":"Tarallo A, Damiano C, Strollo S, et al. Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease. EMBO Mol Med. 2021;13(11):e14434. https:\/\/doi.org\/10.15252\/emmm.202114434.","DOI":"10.15252\/emmm.202114434"},{"issue":"3","key":"8343_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/mgme.1998.2800","volume":"66","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Yan M, Ravenscroft EM, et al. Altered trafficking and turnover of LAMP-1 in Pompe disease-affected cells. Mol Genet Metab. 1999;66(3):179\u201388. https:\/\/doi.org\/10.1006\/mgme.1998.2800.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"8343_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1755-8417-1-6","volume":"1","author":"M Cardone","year":"2008","unstructured":"Cardone M, Porto C, Tarallo A, et al. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics. 2008;1(1):6. https:\/\/doi.org\/10.1186\/1755-8417-1-6.","journal-title":"Pathogenetics"},{"issue":"3","key":"8343_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(24)00518-0","volume":"24","author":"van der Beek Name","year":"2025","unstructured":"van der Beek Name, Theunissen T, van den Hout Jmp, Mtm NAME, van den Hout JMP, Pijnappel WWM, et al. Clinical insights in enzyme replacement therapy for metabolic storage disorders: lessons from Pompe disease. Lancet Neurol. 2025;24(3):230\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(24)00518-0.","journal-title":"The Lancet Neurol"},{"issue":"39","key":"8343_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16390","volume":"16","author":"K Wyatt","year":"2012","unstructured":"Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16(39):1\u2013543. https:\/\/doi.org\/10.3310\/hta16390.","journal-title":"Health Technol Assess"},{"key":"8343_CR12","doi-asserted-by":"publisher","unstructured":"Harlaar L, Hogrel J-Y, Perniconi B, et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93(19):e1756\u201367. https:\/\/doi.org\/10.1212\/WNL.0000000000008441.","DOI":"10.1212\/WNL.0000000000008441"},{"issue":"4","key":"8343_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/jimd.12736","volume":"47","author":"van den Dorpel Jja","year":"2024","unstructured":"van den Dorpel Jja, Mackenbach MJ, Dremmen MHG, et al. Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning. J Inher Metab Disea. 2024;47(4):716\u201330. https:\/\/doi.org\/10.1002\/jimd.12736.","journal-title":"J Inher Metab Disea"},{"key":"8343_CR14","doi-asserted-by":"publisher","unstructured":"Kazi ZB, Desai AK, Berrier KL, et al. Sustained immune tolerance induction in enzyme replacement therapy\u2013treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017;2(16):e94328, 94328. https:\/\/doi.org\/10.1172\/jci.insight.94328.","DOI":"10.1172\/jci.insight.94328"},{"key":"8343_CR15","doi-asserted-by":"publisher","unstructured":"Chien Y-H, Lee N-C, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124(6):e1116\u201325. https:\/\/doi.org\/10.1542\/peds.2008-3667.","DOI":"10.1542\/peds.2008-3667"},{"key":"8343_CR16","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.ymgmr.2022.100929","volume":"33","author":"V Gragnaniello","year":"2022","unstructured":"Gragnaniello V, Pijnappel PWWM, Burlina AP, et al. Newborn screening for Pompe disease in Italy: long-term results and future challenges. Mol Genet Metab Rep. 2022;33:100929. https:\/\/doi.org\/10.1016\/j.ymgmr.2022.100929.","journal-title":"Mol Genet Metab Rep"},{"key":"8343_CR17","doi-asserted-by":"publisher","unstructured":"Sacchini M, Procopio E, Pasquini E, et al. Alpha glucosidase assay on dried blood spot in the early diagnosis of infantile Pompe disease. J Neuromuscul Dis. 2015;2(s1):S53. https:\/\/doi.org\/10.3233\/JND-159047.","DOI":"10.3233\/JND-159047"},{"key":"8343_CR18","doi-asserted-by":"publisher","unstructured":"Parenti G, Medina DL, Ballabio A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol Med. 2021;13(2):e12836. https:\/\/doi.org\/10.15252\/emmm.202012836.","DOI":"10.15252\/emmm.202012836"},{"issue":"6","key":"8343_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","volume":"14","author":"T Fukuda","year":"2006","unstructured":"Fukuda T, Ahearn M, Roberts A, et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther. 2006;14(6):831\u201339. https:\/\/doi.org\/10.1016\/j.ymthe.2006.08.009.","journal-title":"Mol Ther"},{"issue":"9","key":"8343_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/biom10091339","volume":"10","author":"NK Meena","year":"2020","unstructured":"Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules. 2020;10(9):1339. https:\/\/doi.org\/10.3390\/biom10091339.","journal-title":"Biomolecules"},{"issue":"4","key":"8343_CR21","first-page":"723","volume":"23","author":"J Wenk","year":"1991","unstructured":"Wenk J, Hille A, von Figura K. Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int. 1991;23(4):723\u201331.","journal-title":"Biochem Int"},{"issue":"12","key":"8343_CR22","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 2021;20(12):1012\u201326. https:\/\/doi.org\/10.1016\/S1474-4422(21)00241-6.","journal-title":"The Lancet Neurol"},{"issue":"12","key":"8343_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Lafor\u00eat P, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20(12):1027\u201337. https:\/\/doi.org\/10.1016\/S1474-4422(21)00331-8.","journal-title":"The Lancet Neurol"},{"issue":"11","key":"8343_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1089\/hum.2015.033","volume":"26","author":"S Han","year":"2015","unstructured":"Han S, Li S, Bird A, et al. Synergistic efficacy from gene therapy with coreceptor blockade and a \u03b22-agonist in murine Pompe disease. Hum Gene Ther. 2015;26(11):743\u201350. https:\/\/doi.org\/10.1089\/hum.2015.033.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"8343_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ymgme.2019.12.008","volume":"129","author":"DD Koeberl","year":"2020","unstructured":"Koeberl DD, Case LE, Desai A, et al. Improved muscle function in a phase I\/II clinical trial of albuterol in Pompe disease. Mol Genet Metab. 2020;129(2):67\u201372. https:\/\/doi.org\/10.1016\/j.ymgme.2019.12.008.","journal-title":"Mol Genet Metab"},{"key":"8343_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ceca.2017.06.006","volume":"69","author":"S Di Paola","year":"2018","unstructured":"Di Paola S, Scotto-Rosato A, Medina DL. TRPML1: the Ca(2+)retaker of the lysosome. Cell Calcium. 2018;69:112\u201321. https:\/\/doi.org\/10.1016\/j.ceca.2017.06.006.","journal-title":"Cell Calcium"},{"issue":"1","key":"8343_CR27","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1038\/s41467-019-13572-w","volume":"10","author":"A Scotto Rosato","year":"2019","unstructured":"Scotto Rosato A, Montefusco S, Soldati C, et al. TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKK\u03b2\/VPS34 pathway. Nat Commun. 2019;10(1):5630. https:\/\/doi.org\/10.1038\/s41467-019-13572-w.","journal-title":"Nat Commun"},{"issue":"3","key":"8343_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/ncb3114","volume":"17","author":"DL Medina","year":"2015","unstructured":"Medina DL, Di Paola S, Peluso I, et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. Nat Cell Biol. 2015;17(3):288\u201399. https:\/\/doi.org\/10.1038\/ncb3114.","journal-title":"Nat Cell Biol"},{"key":"8343_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/bs.ircmb.2021.03.002","volume":"362","author":"DL Medina","year":"2021","unstructured":"Medina DL. Lysosomal calcium and autophagy. Int Rev Cell Mol Biol. 2021;362:141\u201370. https:\/\/doi.org\/10.1016\/bs.ircmb.2021.03.002.","journal-title":"Int Rev Cell Mol Biol"},{"key":"8343_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ceca.2014.10.008","volume":"58","author":"K Venkatachalam","year":"2015","unstructured":"Venkatachalam K, Wong C-O, Zhu MX. The role of TRPMLs in endolysosomal trafficking and function. Cell Calcium. 2015;58:48\u201356. https:\/\/doi.org\/10.1016\/j.ceca.2014.10.008.","journal-title":"Cell Calcium"},{"issue":"3","key":"8343_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/cdd.2014.150","volume":"22","author":"G Filomeni","year":"2015","unstructured":"Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22(3):377\u201388. https:\/\/doi.org\/10.1038\/cdd.2014.150.","journal-title":"Cell Death Differ"},{"issue":"6","key":"8343_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/mt.2009.53","volume":"17","author":"C Porto","year":"2009","unstructured":"Porto C, Cardone M, Fontana F, et al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther. 2009;17(6):964\u201371. https:\/\/doi.org\/10.1038\/mt.2009.53.","journal-title":"Mol Ther"},{"key":"8343_CR33","doi-asserted-by":"publisher","unstructured":"Ullman JC, Mellem KT, Xi Y, et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci Transl Med. 2024;16(730):eadf1691. https:\/\/doi.org\/10.1126\/scitranslmed.adf1691.","DOI":"10.1126\/scitranslmed.adf1691"},{"key":"8343_CR34","doi-asserted-by":"publisher","first-page":"15053","DOI":"10.1038\/mtm.2015.53","volume":"3","author":"PA Doerfler","year":"2016","unstructured":"Doerfler PA, Nayak S, Corti M, et al. Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther Methods Clin Dev. 2016;3:15053. https:\/\/doi.org\/10.1038\/mtm.2015.53.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"8343_CR35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1080\/15548627.2015.1047130","volume":"11","author":"DL Medina","year":"2015","unstructured":"Medina DL, Ballabio A. Lysosomal calcium regulates autophagy. Autophagy. 2015;11(6):970\u201371. https:\/\/doi.org\/10.1080\/15548627.2015.1047130.","journal-title":"Autophagy"},{"key":"8343_CR36","doi-asserted-by":"publisher","unstructured":"Wang W, Gao Q, Yang M, et al. Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation. Proc Natl Acad Sci USA. 2015;112(11):E1373\u20131381. https:\/\/doi.org\/10.1073\/pnas.1419669112.","DOI":"10.1073\/pnas.1419669112"},{"issue":"3","key":"8343_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.devcel.2011.07.016","volume":"21","author":"DL Medina","year":"2011","unstructured":"Medina DL, Fraldi A, Bouche V, et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell. 2011;21(3):421\u201330. https:\/\/doi.org\/10.1016\/j.devcel.2011.07.016.","journal-title":"Dev Cell"},{"issue":"4","key":"8343_CR38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","volume":"1793","author":"T Braulke","year":"2009","unstructured":"Braulke T, Bonifacino JS. Sorting of lysosomal proteins. Biochim et Biophys Acta (BBA) - Mol Cell Res. 2009;1793(4):605\u201314. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.10.016.","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Res"},{"issue":"28","key":"8343_CR39","doi-asserted-by":"publisher","first-page":"12493","DOI":"10.1073\/pnas.1004232107","volume":"107","author":"LJ Olson","year":"2010","unstructured":"Olson LJ, Peterson FC, Castonguay A, et al. Structural basis for recognition of phosphodiester-containing lysosomal enzymes by the cation-independent mannose 6-phosphate receptor. Proc Natl Acad Sci USA. 2010;107(28):12493\u201398. https:\/\/doi.org\/10.1073\/pnas.1004232107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"8343_CR40","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.bbrc.2017.12.101","volume":"495","author":"H Park","year":"2018","unstructured":"Park H, Kim J, Lee YK, et al. Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease. Biochem Bioph Res Co. 2018;495(4):2418\u201324. https:\/\/doi.org\/10.1016\/j.bbrc.2017.12.101.","journal-title":"Biochem Bioph Res Co"},{"issue":"12","key":"8343_CR41","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1038\/mt.2012.152","volume":"20","author":"C Porto","year":"2012","unstructured":"Porto C, Ferrara MC, Meli M, et al. Pharmacological enhancement of \u03b1-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther. 2012;20(12):2201\u201311. https:\/\/doi.org\/10.1038\/mt.2012.152.","journal-title":"Mol Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08343-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08343-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:44:21Z","timestamp":1781873061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08343-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8343"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08343-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Primary human fibroblasts were obtained from an institutional biobank of anonymized samples originally collected for diagnostic purposes. All patients or legal guardians provided written informed consent for diagnostic procedures and future research use. According to institutional regulations, additional ethical approval was not required for studies performed on fully anonymized cell lines. The study complied with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.B. is a co-founder and shareholder of CASMA Therapeutics Inc. and serves on the advisory boards of Avilar Therapeutics and Amplify Therapeutics. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"792"}}